The Alzheimer’s Drug Discovery Foundation (ADDF) announces $2,315,881 in funding for three new research investments—demonstrating its focus to accelerate and advance the use of biomarkers and potential new treatments to change the course of the disease in patients.
“It is exciting to help bring these important research projects to the next level,” says Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF. “With these new investments, we are addressing the need for the use of biomarkers as a critical tool for diagnosis and disease progression. We are also advancing clinical studies that explore novel therapeutic targets that likely play a critical role in the prevention and treatment of Alzheimer’s disease, such as thrombin inhibitors and stress kinase inhibitors.”
BIOMARKERS
Paul Worley, MD, Johns Hopkins School of…
